Clinical case of de novo anaplastic ganglioglioma and current status of the problem

The authors report a rare case of de novo malignant ganglioglioma (WHO grade III) in a 26-year old female. The patient has complained of periodic feeling fear, anxiety, episodes of impaired consciousness with extremity muscle cramps sometimes followed by urination, as well as flashes before eyes. Computed tomography perfusion and magnetic resonance spectroscopy were carried out for differential diagnosis between different types of tumors. Stereotactic biopsy was performed for histological examination. High surgical risk became a contraindication to gross total resection of the tumor. The patient has received radiation therapy (Trilogy linear accelerator) in a total dose of 60 Gy. The tumor shrank significantly. In 7 months, monitoring MRT did not detect further growth of the tumor. The authors have analyzed the case and reviewed the existing literature data regarding gangliogliomas. Taking into account low prevalence of these tumors (0.4-1% of all brain tumors), especially of their malignant forms (3-10% of gangliogliomas), lack of sufficient data regarding prognostic factors, life expectancy, time of recurrence, lack of accurate indications for different methods of treatment (surgery, radiation, chemotherapy), these tumors still need further research that should also involve supplementary neuroimaging techniques and stereotactic biopsy

NADPH oxidases in Parkinson’s disease: a systematic review

Abstract Parkinson’s disease (PD) is a progressive movement neurodegenerative disease associated with a loss of dopaminergic neurons in the substantia nigra of the brain. Oxidative stress, a condition that occurs due to imbalance in oxidant and antioxidant status, is thought to play an important role in dopaminergic neurotoxicity. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases are multi-subunit enzymatic complexes that generate reactive oxygen species as their primary function. Increased immunoreactivities for the NADPH oxidases catalytic subunits Nox1, Nox2 and Nox4 have been reported in the brain of PD patients. Furthermore, knockout or genetic inactivation of NADPH oxidases exert a neuroprotective effect and reduce detrimental aspects of pathology in experimental models of the disease. However, the connections between NADPH oxidases and the biological processes believed to contribute to neuronal death are not well known. This review provides a comprehensive summary of our current understanding about expression and physiological function of NADPH oxidases in neurons, microglia and astrocytes and their pathophysiological roles in PD. It summarizes the findings supporting the role of both microglial and neuronal NADPH oxidases in cellular disturbances associated with PD such as neuroinflammation, alpha-synuclein accumulation, mitochondrial and synaptic dysfunction or disruption of the autophagy-lysosome system. Furthermore, this review highlights different steps that are essential for NADPH oxidases enzymatic activity and pinpoints major obstacles to overcome for the development of effective NADPH oxidases inhibitors for PD